NYSE$ATR

AptarGroup Inc. · Q1 2022 earnings

Q1 2022 earnings · · Investor relations

Briefing

AptarGroup's Q1 2022 results showed sales growth and strong top-line performance across all segments, indicating recovery from the global pandemic effects.

AptarGroup reported a 9% increase in sales to $845 million, with core sales up 13%. The company experienced double-digit core sales growth in each segment. Reported earnings per share were $0.93, and adjusted earnings per share were $0.96.

  • Reported sales grew 9% and core sales grew 13% with double-digit core growth in each segment.
  • Pharma segment posted sales growth in all markets including the prescription drug division as demand for allergic rhinitis and asthma devices began to recover.
  • Reported earnings per share of $0.93 compared to $1.24 in the prior year.
  • Adjusted earnings per share of $0.96 compared to $1.05 in the prior year.

Headline financials

Total Revenue

$845M

Previous: $777M+8.8%
EPS (adj)

$0.96

Previous: $1.09-11.9%
Total Core Sales Growth

13.0%

Previous: 1.0%+1200.0%
Pharma Core Sales Growth

13.0%

Previous: 0.0%
Beauty Core Sales Growth

10.0%

Previous: -3.0%+433.3%
Closures Core Sales Growth

18.0%

Previous: 14.0%+28.6%
Capital Expenditures

-$73.1M

Previous: -$63.9M-14.4%
Free Cash Flow

-$10.6M

Previous: $20.1M-153.0%
Net Income

$62.4M

Previous: $83.9M-25.6%
Operating Income

$97.7M

Previous: $92.6M+5.5%
Gross Profit

$845M

Previous: $777M+8.8%
Cash & Equivalents

$356M

Previous: $255M+39.5%
Total Assets

$4.41B

Previous: $3.99B+10.4%
Stock-Based Comp

$13.4M

Previous: $11.5M+16.3%

Revenue & EPS history

AptarGroup · Revenue · Quarterly

$845M

Q1 2022+8.8%vs Q1 2021
Beat estimate in 15 of 16 quarters(94%)
ActualEstimate

Revenue by segment

AptarGroup · $845M total across 3 segments · Q1 2022

  • Beauty
    $368M+6.1%
  • Pharma
    $342M+9.1%
  • Closures
    $134M

Forward guidance

Aptar expects earnings per share for the second quarter of 2022, excluding any restructuring expenses, changes in the fair value of equity investments and acquisition costs, to be in the range of $0.92 to $1.02.

Tailwinds

  • We are moving forward into the post-pandemic era and we feel very good about the way our businesses are positioned for long-term growth.
  • Looking forward to the second quarter, we expect the broad based momentum from the first quarter to continue with growth in each segment
  • Including strong growth of our prescription drug device business
  • We will continue to manage our operations efficiently
  • We mitigate rising costs through pricing initiatives and cost containment.

Headwinds

  • Lower demand for at-home COVID-19 tests.
  • The war in Ukraine and the COVID-19 outbreak in China are expected to have some impact on our business in the respective regions
  • Visibility remains highly uncertain.
  • Guidance is based on an effective tax rate range of 27% to 29%
  • Currency translation effects

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2022

Historical avgQ1 2022

+0.3%

Avg return

Earnings day

-0.1%

Avg return

5 days after

+1.2%

Avg return

30 days after

63%

43 / 68 earnings

Positive

+9.2%

Q4 2017

Best reaction

-9.0%

Q3 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-3.3%-0.8%-6.4%
Q4 2025+8.3%+12.9%+6.5%
Q3 2025-9.0%-7.1%+0.3%
Q1 2025+2.3%+2.1%+6.8%
Q4 2024-8.5%-9.4%-2.3%
Q3 2024+0.8%+0.6%+2.3%
Q2 2024+1.7%+1.1%+4.4%
Q1 2024+2.4%+3.1%+5.8%
Q4 2023+5.4%+3.1%+8.6%
Q3 2023+0.1%-0.9%+4.2%
Q2 2023+3.2%+2.1%+6.3%
Q1 2023+2.4%+4.1%-1.4%
Q4 2022+5.7%+4.2%+0.3%
Q3 2022+2.1%-1.9%+6.9%
Q2 2022+1.6%+0.5%-1.5%
Q1 2022+3.4%+2.5%-2.0%
Q4 2021+3.3%+3.8%+2.7%
Q3 2021-3.6%+1.7%+1.0%
Q2 2021-6.3%-6.6%-2.3%
Q1 2021-0.2%+2.6%-2.5%
Q4 2020-7.7%-10.4%-2.7%
Q3 2020+1.6%+6.4%+13.3%
Q2 2020-3.0%-0.2%-0.6%
Q1 2020-3.6%-4.1%+1.2%
Q4 2019-2.6%-7.0%-19.6%
Q3 2019-7.1%-8.9%-6.0%
Q2 2019-5.0%-5.4%-1.3%
Q1 2019+1.3%+2.3%+2.0%
Q4 2018+1.5%+0.0%+2.2%
Q3 2018+1.8%+2.1%+2.0%
Q2 2018+8.6%+8.1%+9.6%
Q1 2018+0.3%+0.4%+1.0%
Q4 2017+9.2%+11.8%+9.6%
Q3 2017-0.6%-1.6%-2.5%
Q2 2017-6.5%-6.3%-6.4%
Q1 2017+1.2%+1.1%+6.3%
Q4 2016+1.7%+0.4%+4.4%
Q3 2016-4.3%-7.4%-0.3%
Q2 2016-1.9%-3.9%-1.6%
Q1 2016-3.1%
Q4 2015-2.8%
Q3 2015+2.4%
Q2 2015+8.3%
Q1 2015+2.4%
Q4 2014+1.8%
Q3 2014+2.0%
Q2 2014-3.5%
Q1 2014-0.1%
Q4 2013+1.9%
Q3 2013+0.2%
Q2 2013-2.1%
Q1 2013-2.0%
Q4 2012-0.8%
Q3 2012-3.5%
Q2 2012+2.6%
Q1 2012+0.9%
Q4 2011+0.1%
Q3 2011+5.8%
Q2 2011-5.0%
Q1 2010+2.2%
Q1 2011+2.3%
Q4 2008+1.5%
Q4 2010+1.5%
Q3 2010+2.9%
Q3 2009+2.9%
Q4 2009+0.5%
Q2 2009+0.5%
Q2 2010+0.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro